We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
-21.57%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$47.9M
Cap. Flow
+$7.45M
Cap. Flow %
4.46%
Top 10 Hldgs %
98.53%
Holding
14
New
2
Increased
–
Reduced
2
Closed
1
Avg Time Held
0.9 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
EVAR
Lombard Medical
EVAR
+$22.2M
2
EPRS
Epirus Biopharmaceuticals
EPRS
+$68.3K

Sector Composition

Rank Sector Weight
1 Healthcare 67.7%
2 Miscellaneous 32.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
RNA icon
1
DELISTED
Prosensa Holdings
RNA
$52.4M 31.32%
6,213,924
– –
2013 Q3
4 quarters
EVAR
2
DELISTED
Lombard Medical
EVAR
$25.6M 15.33%
+3,352,544
New +$22.2M
2014 Q3
0 quarters
SUPN icon
3
DELISTED
Supernus Pharmaceuticals
SUPN
$25M 14.96%
2,879,328
-720,672
-20% -$6.51M
2013 Q2
5 quarters
PTLA
4
DELISTED
Portola Pharmaceuticals
PTLA
$23.5M 14.07%
930,682
-310,230
-25% -$8.17M
2013 Q2
5 quarters
DRNA
5
DELISTED
Dicerna Pharmaceuticals
DRNA
$15M 8.99%
1,182,196
– –
2014 Q1
2 quarters
AMRN icon
6
Amarin
AMRN
$473M
$8.82M 5.27%
404,374
– –
2013 Q2
5 quarters
CEMP
7
DELISTED
Cempra
CEMP
$7.83M 4.68%
714,285
– –
2013 Q2
5 quarters
ZGNX
8
DELISTED
Zogenix
ZGNX
$2.69M 1.61%
291,902
– –
2013 Q2
5 quarters
RGLS icon
9
DELISTED
Regulus Therapeutics
RGLS
$2.24M 1.34%
2,728
– –
2014 Q1
2 quarters
QUIT icon
10
Achieve Life Sciences
QUIT
$647M
$1.6M 0.96%
274
– –
2013 Q2
5 quarters
HPTX
11
DELISTED
Hyperion Therapeutics
HPTX
$1.58M 0.94%
62,500
– –
2013 Q2
5 quarters
ANTH
12
DELISTED
Anthera Pharmaceuticals
ANTH
$832K 0.5%
54,749
– –
2013 Q2
5 quarters
EPRS
13
DELISTED
Epirus Biopharmaceuticals
EPRS
$56K 0.03%
+7,896
New +$68.3K
2014 Q3
0 quarters
ZLCS
14
DELISTED
Zalicus
ZLCS
– –
-78,966
Closed -$96K –

Similar funds

Abingworth's Q3 2014 Portfolio in Review

As of Q3 2014, Abingworth held 14 positions worth $167M, down 22% from $215M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Abingworth deployed $7.45M of net new capital in Q3 2014, opening 2 new positions. Its largest new stake was Lombard Medical: 3,352,544 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Portola Pharmaceuticals, an estimated $8.17M trimmed.

  • Abingworth's largest Q3 2014 buy was Lombard Medical: 3,352,544 shares worth $25.6M.
  • Abingworth's biggest Q3 2014 reduction was Portola Pharmaceuticals, cutting an estimated $8.17M.
  • Abingworth fully exited Zalicus in Q3 2014, selling an estimated $96K.
  • Abingworth's ten largest holdings make up 99% of its $167M portfolio in Q3 2014.
  • Abingworth opened 2 new positions and closed 1 in Q3 2014.
  • Abingworth's portfolio value fell 22% quarter-over-quarter to $167M.

Based on Abingworth's 13F filing for Q3 2014, filed 14 Nov 2014.